Last reviewed · How we verify
Transplantation of Deceased Donors With COVID-19 Into COVID-19 Negative Recipients Utilizing Casirivimab and Imdevimab Antibody Cocktail
This study will look to increase the donor pool for the solid organ transplant population by transplanting patients who died with COVID-19 but not from COVID-19 utilizing casirivimab and imdevimab antibody cocktail to prevent the transmission of the virus.
Details
| Lead sponsor | Northwell Health |
|---|---|
| Phase | Phase 1 |
| Status | WITHDRAWN |
| Start date | 2022-01 |
| Completion | 2025-01 |
Conditions
- COVID-19
- Organ Transplant
Interventions
- Casirivimab and Imdevimab Antibody Cocktail
Primary outcomes
- Monitoring for SARS-CoV-2 infection — 30 days
The overall objective of the study is to have transplant COVID-19 positive organs into COVID-19 negative recipients with no transmission of the virus. This will be assessed by monitoring for SARS-CoV-2 infection at different time points post-transplantation.
Countries
United States